Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rational design and development of RDP58.

Suhasini Iyer1, Roger Lahana, Roland Buelow

  • 1Sangstat Medical Corporation, Fremont, CA 94555, USA. siyer@sangstat.com

Current Pharmaceutical Design
|October 9, 2002
PubMed
Summary

Novel immunomodulatory peptides, including RDP58, were developed using rational design. RDP58 inhibits TNF production and upregulates heme oxygenase-1 (HO-1) activity, showing potential in disease models.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of CD38 enzyme activity on engrafted human immune cells enhances NAD+ metabolism and inhibits inflammation in an <i>in-vivo</i> model of xeno-GvHD.

Frontiers in immunology·2025
Same author

Evaluating DFHBI-Responsive RNA Light-Up Aptamers as Fluorescent Reporters for Gene Expression.

ACS synthetic biology·2023
Same author

A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.

Oncoimmunology·2022
Same author

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity.

mAbs·2022
Same author

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.

Journal for immunotherapy of cancer·2021
Same author

A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells.

Scientific reports·2021

Area of Science:

  • Immunology
  • Drug Discovery
  • Computational Chemistry

Background:

  • Immune modulation is critical for treating various diseases.
  • Peptides derived from HLA I offer potential for immune response modulation.
  • Targeting T lymphocyte interactions is a key strategy in immunotherapy.

Purpose of the Study:

  • To develop novel immunomodulatory peptides using a rational design approach.
  • To identify peptides with dual biological activities: TNF inhibition and HO-1 upregulation.
  • To evaluate the therapeutic potential of developed peptides in disease models.

Main Methods:

  • Utilized topological and shape descriptors with molecular dynamics for rational peptide design.
  • Generated and screened a virtual combinatorial peptide library (279,936 peptides).
  • Synthesized and tested lead candidates, including RDP58, in vitro and in vivo.

Main Results:

  • Identified RDP58, a peptide with significant immunomodulatory properties.
  • RDP58 demonstrated inhibition of Tumor Necrosis Factor (TNF) production.
  • RDP58 showed upregulation of heme oxygenase-1 (HO-1) activity and prolonged graft survival in vivo.

Conclusions:

  • Rational design successfully yielded novel immunomodulatory peptides like RDP58.
  • RDP58 exhibits dual therapeutic potential by inhibiting TNF and upregulating HO-1.
  • RDP58 shows promise for alleviating symptoms across various experimental disease models.

Related Experiment Videos